Trial Profile
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Volasertib (Primary)
- Indications Bladder cancer; Renal cancer; Urethral cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 27 Oct 2011 Actual number of patients (n= 50) reported by ClinicalTrials.gov
- 19 Oct 2011 Status changed from active, no longer recruiting to completed on 1 Sep 2011 as reported by ClinicalTrials.gov
- 04 May 2011 Planned end date changed from 1 Jun 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.